JP2024524388A5 - - Google Patents

Info

Publication number
JP2024524388A5
JP2024524388A5 JP2023580537A JP2023580537A JP2024524388A5 JP 2024524388 A5 JP2024524388 A5 JP 2024524388A5 JP 2023580537 A JP2023580537 A JP 2023580537A JP 2023580537 A JP2023580537 A JP 2023580537A JP 2024524388 A5 JP2024524388 A5 JP 2024524388A5
Authority
JP
Japan
Prior art keywords
seq
complement
position corresponding
adenine
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524388A (ja
JP2024524388A6 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/035846 external-priority patent/WO2023278787A2/en
Publication of JP2024524388A publication Critical patent/JP2024524388A/ja
Publication of JP2024524388A5 publication Critical patent/JP2024524388A5/ja
Publication of JP2024524388A6 publication Critical patent/JP2024524388A6/ja
Pending legal-status Critical Current

Links

JP2023580537A 2021-07-02 2022-06-30 Wntファミリーメンバー5B(WNT5B)阻害剤での低下した骨塩密度の処置 Pending JP2024524388A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163218209P 2021-07-02 2021-07-02
US63/218,209 2021-07-02
PCT/US2022/035846 WO2023278787A2 (en) 2021-07-02 2022-06-30 Treatment of decreased bone mineral density with wnt family member 5b (wnt5b) inhibitors

Publications (3)

Publication Number Publication Date
JP2024524388A JP2024524388A (ja) 2024-07-05
JP2024524388A5 true JP2024524388A5 (cg-RX-API-DMAC7.html) 2025-07-07
JP2024524388A6 JP2024524388A6 (ja) 2025-08-08

Family

ID=82839088

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580537A Pending JP2024524388A (ja) 2021-07-02 2022-06-30 Wntファミリーメンバー5B(WNT5B)阻害剤での低下した骨塩密度の処置

Country Status (10)

Country Link
US (1) US20230083558A1 (cg-RX-API-DMAC7.html)
EP (1) EP4363586A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024524388A (cg-RX-API-DMAC7.html)
KR (1) KR20240043753A (cg-RX-API-DMAC7.html)
CN (1) CN117940565A (cg-RX-API-DMAC7.html)
AU (1) AU2022302084A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225083A1 (cg-RX-API-DMAC7.html)
IL (1) IL309644A (cg-RX-API-DMAC7.html)
MX (1) MX2023015271A (cg-RX-API-DMAC7.html)
WO (1) WO2023278787A2 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090047276A1 (en) * 2007-05-15 2009-02-19 University Of Washington Methods for increasing cell or tissue regeneration in a vertebrate subject
WO2017023973A1 (en) * 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof

Similar Documents

Publication Publication Date Title
Kim et al. Plasma membrane calcium ATPase regulates bone mass by fine-tuning osteoclast differentiation and survival
Burke et al. Synergistic expression of the CXCL10 gene in response to IL-1β and IFN-γ involves NF-κB, phosphorylation of STAT1 at Tyr701, and acetylation of histones H3 and H4
KR101770435B1 (ko) 자연 안티센스 전사체가 아포리포단백질-a1로 억제에 의해 아포리포단백-a1 관련된 질환의 치료
Li et al. TWIST1 associates with NF-κ B subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production
Shi et al. Gene expression profiling in the developing rat brain exposed to ketamine
ES2632212T3 (es) miR-135 y composiciones que lo comprenden para el tratamiento de afecciones médicas asociadas con la serotonina
Sun et al. TRPM2-mediated feed-forward loop promotes chondrocyte damage in osteoarthritis via calcium-cGAS-STING-NF-κB pathway
JP2009521934A (ja) 薬物標的としての天然アンチセンスおよび非コードrna転写物
Cao et al. Hoxa5 promotes adipose differentiation via increasing DNA methylation level and inhibiting PKA/HSL signal pathway in mice
Yin et al. CircRNA hsa_circ_0006859 inhibits the osteogenic differentiation of BMSCs and aggravates osteoporosis by targeting miR-642b-5p/miR-483-3p and upregulating EFNA2/DOCK3
Cai et al. LSD1 inhibition circumvents glucocorticoid-induced muscle wasting of male mice
JP2002525081A (ja) 低酸素により調節される遺伝子転写に特徴的な配列
Kitamura et al. Interferon-α exerts proinflammatory properties in experimental radiation-induced esophagitis: possible involvement of plasmacytoid dendritic cells
Zhang et al. ULK1 Suppresses Osteoclast Differentiation and Bone Resorption via Inhibiting Syk‐JNK Through DOK3
JP2024524375A5 (cg-RX-API-DMAC7.html)
Kim et al. Dexamethasone differentially regulates renal and duodenal calcium‐processing genes in calbindin‐D9k and‐D28k knockout mice
US7169559B2 (en) LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
JP2024528284A5 (cg-RX-API-DMAC7.html)
US12509687B2 (en) Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors
JP2009516710A (ja) eIF4E−BP2の発現のモジュレート
KR20080106415A (ko) 유전자 발현을 조절하기 위한 조성물의 제조에서 dha 및ara의 용도
CN101384619A (zh) 骨形成的调节
US20160101111A1 (en) Combined inhibition of the vitamin d receptor and poly(adp) ribose polymerase (parp) in the treatment of cancer
US20240254489A1 (en) Compositions and methods of targeting the pax6 signaling pathway to reduce formation of amyloid beta plaques and neurofibrillary tangles
WO2008066744A9 (en) Methods and compositions for treating and preventing spinal cord injury and other neuronal disease or injury